Studies of the glucagon-like peptide-1 receptor (GLP-1R) expression across various human tumors have found it predominantly in specific endocrine, embryonal, and brain tumors, but it is notably scarce or absent in most carcinomas [4,5]. This evidence concerns the gene GLP1R and carcinoma.